Qsymia

Caloric Restriction, Obesity, Type 2 Diabetes + 6 more
Treatment
3 FDA approvals
20 Active Studies for Qsymia

What is Qsymia

PhentermineThe Generic name of this drug
Treatment SummaryPhentermine is a drug used to help people lose weight by reducing appetite. It was introduced in 1959 and is classified as a Schedule IV drug, meaning it has a low potential for abuse. It is related to amphetamine but does not have the same addictive qualities. Phentermine was initially combined with other drugs to create an anti-obesity regime, but was later approved as a stand-alone drug in 2012. It is typically used in short-term weight management programs and is taken in lower doses than when it was combined with other drugs.
Ionaminis the brand name
image of different drug pills on a surface
Qsymia Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ionamin
Phentermine
1959
298

Approved as Treatment by the FDA

Phentermine, also known as Ionamin, is approved by the FDA for 3 uses including Obesity and Comorbidity .
Obesity
Used to treat Obesity in combination with Topiramate
Comorbidity
Used to treat one related comorbidity in combination with Topiramate
Regime of weight reduction

Effectiveness

How Qsymia Affects PatientsPhentermine is thought to work by reducing appetite and increasing the body's resting energy expenditure. In clinical studies, patients taking phentermine lost an average of 3.6 kg over two to twenty-four weeks and were able to maintain their weight after treatment stopped. Unlike other drugs in the amphetamine family, phentermine does not cause any stimulation of the central nervous system, high blood pressure, tolerance or QTc prolongation.
How Qsymia works in the bodyPhentermine is a medication that helps reduce hunger by increasing levels of noradrenaline in the brain. This causes the body to enter a state of alertness, which suppresses the feeling of hunger. It also weakly inhibits monoamine oxidase, although this effect is not usually significant.

When to interrupt dosage

The measure of Qsymia is contingent upon the specified disorder, comprising Regime of weight reduction, Hyperlipidemia and Type 2 Diabetes. The amount likewise deviates as per the technique of delivery (e.g. Oral or Tablet) articulated in the table hereunder.
Condition
Dosage
Administration
Obesity
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Caloric Restriction
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Type 2 Diabetes
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Hypertensive disease
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
High Cholesterol
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Regime of weight reduction
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Chronic Weight Management therapy
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
increase in physical activity
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Comorbidity
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Warnings

Qsymia has seven forbidden contraindications, so it is not advised to take Qsymia when suffering from any of the conditions in the below table.Qsymia Contraindications
Condition
Risk Level
Notes
Hyperthyroidism
Do Not Combine
concomitant use or 14 days after discontinuation
Do Not Combine
Agitation
Do Not Combine
Drug abuse
Do Not Combine
Cardiovascular Diseases
Do Not Combine
Open-angle glaucoma
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Phentermine may interact with Pulse Frequency
There are 20 known major drug interactions with Qsymia.
Common Qsymia Drug Interactions
Drug Name
Risk Level
Description
Iobenguane
Major
Phentermine can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methylene blue
Major
Phentermine may increase the serotonergic activities of Methylene blue.
Mirtazapine
Major
Phentermine may increase the serotonergic activities of Mirtazapine.
1-benzylimidazole
Minor
The therapeutic efficacy of 1-benzylimidazole can be decreased when used in combination with Phentermine.
4-Methoxyamphetamine
Minor
The risk or severity of hypertension can be increased when Phentermine is combined with 4-Methoxyamphetamine.
Qsymia Toxicity & Overdose RiskThe toxic dose of phentermine for rats is 151mg/kg. Signs of an overdose may include restlessness, tremors, rapid breathing, confusion, aggression, hallucinations, and panic followed by fatigue and depression. It can also cause irregular heartbeat, high or low blood pressure, stomach issues such as nausea, vomiting, and abdominal cramps. Chronic overdosing may lead to skin problems, difficulty sleeping, irritability, hyperactivity, and changes in personality. In severe cases, it may cause a psychosis similar to schizophrenia. Carcinogenic or mutagenic effects have not been observed.
image of a doctor in a lab doing drug, clinical research

Qsymia Novel Uses: Which Conditions Have a Clinical Trial Featuring Qsymia?

There are 104 active studies investigating the potential of Qsymia to treat Type 2 Diabetes, facilitate Weight Reduction Regimens and ameliorate Disease.
Condition
Clinical Trials
Trial Phases
Type 2 Diabetes
96 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1
Obesity
0 Actively Recruiting
Hypertensive disease
0 Actively Recruiting
Comorbidity
0 Actively Recruiting
High Cholesterol
17 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Early Phase 1
Caloric Restriction
0 Actively Recruiting
Regime of weight reduction
0 Actively Recruiting
increase in physical activity
0 Actively Recruiting
Chronic Weight Management therapy
0 Actively Recruiting

Qsymia Reviews: What are patients saying about Qsymia?

5Patient Review
9/13/2022
Qsymia for Weight Loss Management for an Obese Person
I've been on this medication for six months and have lost 50 pounds. I started at 208 and was considered obese; now I'm just overweight with a BMI of 28. I'm still taking the medication and planning to lose 25 more pounds.
4.7Patient Review
4/29/2022
Qsymia for Weight Gain
I'm really happy with this medication. I've been able to keep the weight off that I lost, and my cravings are mostly under control.
4.7Patient Review
10/29/2021
Qsymia for Weight Loss Management for Overweight Person with BMI 27 to 29 and Weight-Related Comorbidity
I've been seeing some great results. I lost 25 pounds in the first three weeks while taking this medication. I'm currently still on the 7mg dose and have experienced some fatigue; however, I believe this could be my body getting used to the medicine. Overall, I'm pleased with how things are going and plan to continue using this treatment.
4Patient Review
5/14/2022
Qsymia for Weight Gain
This pill is working great for me! I started it last Sunday and by the following Saturday, I had lost 9 pounds. I'm going on vacation in 20 days and need to lose 10 pounds to hit my weight goal, so this is perfect. I'm currently taking 15 mg per day and am down to 140 pounds from 149.
4Patient Review
12/8/2021
Qsymia for Weight Loss Management for Overweight Person with BMI 27 to 29 and Weight-Related Comorbidity
I started this treatment two days ago and have had headaches that I hope will go away. I've been looking online to see if anyone else has experienced this symptom and whether or not it goes away. I'm hopeful that this works because my hip is in terrible shape and I've gained a lot of weight because my mobility is so limited.
3Patient Review
6/22/2021
Qsymia for Weight Loss Management for Overweight Person with BMI 27 to 29 and Weight-Related Comorbidity
I was really pleased with the results I got from taking Qsymia, but as soon as I had to switch to the generic version, I started noticing weight gain. Not cool.
2.3Patient Review
1/4/2022
Qsymia for Weight Loss Management for an Obese Person
The first month, I saw some results with this treatment plan; however, I haven't lost any more weight since then. Additionally, I experienced a rare side effect where my speech was impacted. It became difficult to retrieve words I wanted to say, even though I knew what I wanted to communicate.
2.3Patient Review
10/17/2022
Qsymia for Adjunct Treatment of Obesity in a Comprehensive Weight Reduction Regimen
I've now been on this medication for a month and I have not seen any results. I'm 54 years old, so maybe it just doesn't work for people of my age/gender.
1.7Patient Review
12/22/2020
Qsymia for Weight Loss Management for an Obese Person
The first day I started taking Qsymia, I noticed a significant decline in my vision. After two years of taking the medication, I was hospitalized three times with kidney stones. It wasn't until after this that I realized that Qsymia can cause serious kidney problems. The side effects of this drug are terrible and hidden from many people who take it.
1.7Patient Review
7/23/2022
Qsymia for Weight Loss Management for Overweight Person with BMI 27 to 29 and Weight-Related Comorbidity
I was extremely disappointed with this product. I saw no results after a month of use, despite following the recommended diet and exercise regimen
1.7Patient Review
2/5/2022
Qsymia for Weight Loss Management for Overweight Person with BMI 27 to 29 and Weight-Related Comorbidity
I was really disappointed with this treatment. I didn't experience any side effects, but after six months of being on the highest dosage, I actually gained weight.
1Patient Review
7/8/2022
Qsymia for Weight Loss Management for Overweight Person with BMI 27 to 29 and Weight-Related Comorbidity
I've only just started taking the medication, but I already had a terrible experience with customer service. The representative was so rude and unhelpful. It made me feel like my concerns didn't matter at all.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about qsymia

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Qsymia stronger than phentermine?

"There are no studies that compare phentermine and topiramate directly, but experts believe that topiramate is a stronger weight loss medication than phentermine alone."

Answered by AI

What are side effects of Qsymia?

"You may experience dizziness, drowsiness, a dry mouth, difficulty sleeping, tiredness, tingling in your hands and feet, constipation, or a metallic taste. If any of these effects last longer than a few days or get worse, tell your doctor or pharmacist."

Answered by AI

How fast do you lose weight on Qsymia?

"My results have been good. I lost 25 pounds in the first 3 weeks - two weeks while taking 3.5mg of the medication and one week while taking 7mg of the medication."

Answered by AI

How does Qsymia work for weight loss?

"Phentermine is a drug that causes an immediate response, while Topiramate works throughout the day. The combination of the two drugs helps to reduce your levels of hunger and promote weight loss more effectively than diet and exercise alone. On average, people who take these drugs lose 5-8.9% of their excess body weight."

Answered by AI

Clinical Trials for Qsymia

Image of Lipid Clinic at Brown University Health in Providence, United States.

2-HOBA Supplementation for High Cholesterol

18 - 69
All Sexes
Providence, RI
The goal of this clinical trial is to learn if a natural supplement called 2-hydroxybenzylamine (2-HOBA) can reduce harmful oxidized lipids and improve the function of lipoprotein(a) in adults with high lipoprotein(a) levels. The main questions it aims to answer are: Does 2-HOBA lower oxidized phospholipids on lipoprotein(a)? Does 2-HOBA reduce markers of inflammation and blood clotting in the blood? Participants will: Take 2-HOBA capsules (400 mg, three times daily with meals) for 6 weeks Provide blood and urine samples at the beginning, middle, and end of the study Have lab tests to measure changes in lipids, inflammation, and clotting markers
Waitlist Available
Has No Placebo
Lipid Clinic at Brown University HealthWenliang Song, MD
Have you considered Qsymia clinical trials? We made a collection of clinical trials featuring Qsymia, we think they might fit your search criteria.Go to Trials
Image of Sidney & Lois Eskenazi Hospital in Indianapolis, United States.

Composite Intervention for Metabolic Syndrome

18+
All Sexes
Indianapolis, IN
The objective of this study is to pilot a multifaceted, optimized intervention for metabolic syndrome (MetS) in emergency department patients to establish feasibility. Participants (n=20) will be randomized to intervention or control (usual care). The composite intervention will include an educational video outlining the adverse effects of MetS and the benefit of walking, a written exercise prescription with a defined goal of walking 150 minutes per week, a Fitbit accelerometer device, resources for healthy eating practices, periodic text message reminders, and an urgent referral to primary care and our health system's Healthy Me clinic for follow-up visit. Investigators hypothesize that this approach will change patient understanding and motivation to increase physical activity and healthy eating habits.
Recruiting
Has No Placebo
Sidney & Lois Eskenazi Hospital
Image of Duke University Medical Center in Durham, United States.

Cardiometabolic Prevention Clinic for Cardiovascular Disease

18+
All Sexes
Durham, NC
This project is studying whether a team-based specialty clinic can help people with type 2 diabetes and heart disease better manage their blood pressure and cholesterol. The clinic includes coordinated care from heart doctors, kidney doctors, diabetes specialists, and liver doctors. The study will compare two groups of patients: one receiving usual care from their primary care provider, and one referred to the Duke Cardiometabolic Prevention Clinic for multidisciplinary care. The main goals are to find out if this clinic improves blood pressure and cholesterol control over 12 months, increases use of recommended heart medications, and reduces hospital visits and other healthcare use. Participants will be randomly assigned to one of the two groups. Those referred to the clinic will: 1) Meet with a cardiologist for an initial evaluation. 2) Be referred to other specialists (such as endocrinology, nephrology, or hepatology) based on their needs. 3) Receive ongoing, coordinated care from a team of specialists working together to improve their heart and metabolic health.
Recruiting
Has No Placebo
Duke University Medical CenterNeha J Pagidipati, MD, MPH
Image of Southern GA - Colquitt County in Ellenton, United States.

Sisters of Heart for Improving Heart Health

18 - 45
Female
Ellenton, GA
The goal of this hybrid Type 1 effectiveness-implementation trial is to test the extent to which a peer support and community resource navigation intervention improves psychological well-being, addresses social determinants of health and thus reduces cardiometabolic risk among rural, migrant, low-income farmworker women aged 18-45 years. The main questions it aims to answer are: * If and to what extent does the intervention reduce stress, social isolation, and psychological distress by improving social support and access to needed resources? * If and to what extent does the intervention improve cardiometabolic health, measured by the American Heart Association's Life's Essential 8 (LE8) score? Researchers will compare the CHW-led Sisters of Heart (Hermanas de Corazón) intervention to a Basic intervention (LE8 assessment and resource information) to assess the effect of peer support and community resource navigation on heart health outcomes.
Recruiting
Has No Placebo
Southern GA - Colquitt CountyErin Ferranti, PhD
Have you considered Qsymia clinical trials? We made a collection of clinical trials featuring Qsymia, we think they might fit your search criteria.Go to Trials
Image of UNC Lineberger Comprehensive Cancer Center in Chapel Hill, United States.

Support Program for Caregivers of Patients with Cancer and Diabetes

18 - 99
All Sexes
Chapel Hill, NC
This study investigates the feasibility, acceptability, and preliminary efficacy of enCompass Humana, a social support intervention for caregivers of patients with cancer and diabetes. The enCompass program aims to improve support for these caregivers through a randomized feasibility study of a pilot-tested coaching and navigation program. Caregiver services and system-level support are essential, but successful interventions for cancer caregivers are rarely standardized or systematically disseminated. Consequently, many programs do not reach the most underserved caregivers. Challenges to implementation include substantial clinical staff involvement, lack of dissemination and implementation information, and failure to tailor interventions to rural contexts. Despite the lack of standardized supportive interventions, national reports and legislative efforts increasingly recognize the need to support caregivers. Caregivers reported unmet needs in all domains of social support, including instrumental help (e.g., in-home help, housekeeping), logistical and coordination support (e.g., food delivery, accompanying patients to appointments), information about illness and progression, emotional support, self-care guidance, and financial assistance (e.g., parking costs, lost wages). Caregivers show high interest in services but cited uncertainty and lack of strategies for accessing resources. Many are unaware of existing services. Interviews with oncology clinicians and healthcare administrators revealed similar findings: resources exist, but there is no system to match them with caregivers' needs. Preliminary data suggest the intervention improves caregiver coping self-efficacy and reduces anxiety and depression in patients. With input from stakeholders, including caregivers, patients, family caregiving experts, and clinical care experts, the study team adapted the CARING application into enCompass to mitigate structural barriers and normalize support-seeking. The long-term goal is to adapt this psychosocial support program to increase self-efficacy, support-seeking, and reduce loneliness among caregivers. It is hypothesized that enCompass will build self-efficacy and coping skills, serving caregivers throughout the patient's illness and complications.
Recruiting
Has No Placebo
UNC Lineberger Comprehensive Cancer CenterErin E Kent, PhD
Image of Virginia Commonwealth University in Richmond, United States.

Endovascular Treatment for Stroke

18+
All Sexes
Richmond, VA
Endovascular therapy (EVT) has proven to be more beneficial for patients with AIS caused by large vessel occlusions (LVO) than medical management alone. A recent meta-analysis of 5 RCTs showed that EVT significantly reduced disability at 90 days compared to medical management \[1\]. Despite its obvious benefits, patients may have neurological deterioration despite successful thrombectomy due to ischemia progression, intracranial hemorrhage, re-occlusion, or vasogenic edema. The incidence of early neurological deterioration (END) following EVT for acute stroke has been reported to be ranging from 14.1-35.2% with some studies defining END up to 7 days and some restricting the definition between 6-72 hours post thrombectomy. A small proportion of these patients, approximately 5.9-10.5%, experienced sICH following EVT. Whether END occurs due to ischemic or hemorrhagic it leads to worse outcomes.
Waitlist Available
Has No Placebo
Virginia Commonwealth UniversityAarti Sarwal
Have you considered Qsymia clinical trials? We made a collection of clinical trials featuring Qsymia, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security